UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.07. | Submission of Matters to a Vote of Security Holders. |
On June 4, 2025, Oscar Health, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). As of the close of business on April 10, 2025 (the “Record Date”), there were 218,993,334 shares of Class A common stock outstanding, each share being entitled to one vote, and 35,514,201 shares of Class B common stock outstanding, each share of Class B common stock being entitled to 20 votes (the Class A common stock and Class B common stock, collectively, the “Common Stock”). Accordingly, as of the Record Date, there were 218,993,334 Class A common stock votes and 710,284,020 Class B common stock votes, respectively, available to be cast, for a total of 929,277,354 votes available to be cast. At the Annual Meeting, the holders of 825,961,296 votes of the Common Stock were represented in person or by proxy, constituting a quorum. The following are the voting results for the proposals considered and voted upon at the meeting, each of which were described in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April 25, 2025.
Item 1 - Election of nine directors to hold office until the Annual Meeting of Stockholders to be held in 2026 and until each such director’s respective successor is elected and qualified or until each such director’s earlier death, resignation or removal.
| Nominee | Votes FOR | Votes WITHHELD |
Broker Non-Votes |
|||||||||
| Mark T. Bertolini |
804,091,684 | 597,522 | 21,272,090 | |||||||||
| Jeffery H. Boyd |
782,387,037 | 22,302,169 | 21,272,090 | |||||||||
| William Gassen III |
802,977,371 | 1,711,835 | 21,272,090 | |||||||||
| Joshua Kushner |
799,155,298 | 5,533,908 | 21,272,090 | |||||||||
| Laura Lang |
804,115,105 | 574,101 | 21,272,090 | |||||||||
| David Plouffe |
802,917,236 | 1,771,970 | 21,272,090 | |||||||||
| Siddhartha Sankaran |
799,050,948 | 5,638,258 | 21,272,090 | |||||||||
| Mario Schlosser |
799,010,773 | 5,678,433 | 21,272,090 | |||||||||
| Vanessa A. Wittman |
803,904,202 | 785,004 | 21,272,090 | |||||||||
Item 2 - Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
| Votes FOR | Votes AGAINST | Votes ABSTAINED | Broker Non-Votes | |||
| 825,271,165 | 581,597 | 108,534 | 0 |
Item 3 - Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers.
| Votes FOR | Votes AGAINST | Votes ABSTAINED | Broker Non-Votes | |||
| 801,338,734 | 3,246,195 | 104,277 | 21,272,090 |
Based on the foregoing votes, the nine director nominees were elected, and Items 2 and 3 were approved.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Oscar Health, Inc. | ||||||
| Date: June 6, 2025 | By: | /s/ Adam McAnaney | ||||
| Adam McAnaney | ||||||
| Chief Legal Officer | ||||||